ESR2 and breast carcinoma: Previous studies (Zhu et al. 2019) have identified specific immune gene expression patterns that distinguish Luminal A from Luminal B breast cancer and showed that these distinct immune signatures were associated with a differential ratio between ESR1 and ESR2, a higher value of which has been associated with poorer survival outcomes.